Company Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:05:28 13/03/2026 pm IST			5-day change	1st Jan Change
71.00 ^GBX	-1.39%		+5.19%	+22.41%

24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT

Business description: Avacta Group Plc

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Number of employees: 151

Sales by Activity: Avacta Group Plc

Fiscal Period: December	2020 (GBP)	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)
Therapeutics	16.25L	21.62L	54.81L	20.55L	1L
Diagnostics	5L	8L	41.72L	2.12Cr	-
Animal Health	14.92L	-	-	-	-

See all business segments

Geographical breakdown of sales: Avacta Group Plc

Fiscal Period: December	2020 (GBP)	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)
South Korea	-	14L	54.81L	20.55L	1L
Rest of World	-	-	-	6L	-
France	-	-	12.96L	41.2L	-
Rest of Asia	-	74T	7T	-	-
Rest of Europe	7L	1L	2L	36.88L	-
North America	4L	8L	2L	21T	-
Asia	14.73L	-	-	-	-
United Kingdom	10.76L	5L	25.32L	1.28Cr	-

See all geographic segments

Executive Committee: Avacta Group Plc

Manager	Title	Age	Since
Christina Coughlin CEO	Chief Executive Officer	56	01/04/2024
Brian Hahn DFI	Director of Finance/CFO	51	22/01/2025
Francis X. Wilson CTO	Chief Tech/Sci/R&D Officer	-	09/02/2026
David Liebowitz CTO	Chief Tech/Sci/R&D Officer	-	01/07/2025

See AVACTA GROUP PLC governance

Composition of the Board of Directors: Avacta Group Plc

Director	Title	Age	Since
Paul Fry BRD	Director/Board Member	60	03/02/2020
Mark Goldberg BRD	Director/Board Member	71	17/08/2021
Christina Coughlin BRD	Director/Board Member	56	18/03/2022
Shaun Chilton CHM	Chairman	59	24/06/2024
David Bryant BRD	Director/Board Member	59	28/05/2025
Richard Hughes BRD	Director/Board Member	58	28/05/2025

Composition of the Board of Directors

Shareholders: Avacta Group Plc

Name	Equities	%	Valuation
Hargreaves Lansdown Fund Managers Ltd. 8.027 %	3,53,51,000	8.027 %	32 M p
Lombard Odier Asset Management (Europe) Ltd. 2.648 %	1,16,62,726	2.648 %	11 M p
Conifer Management LLC 2.648 %	1,16,62,726	2.648 %	11 M p
IG Markets Ltd. 2.588 %	1,13,98,000	2.588 %	10 M p
HSBC Global Asset Management (UK) Ltd. 1.607 %	70,79,000	1.607 %	6 M p

List of AVACTA GROUP PLC shareholders

Company details: Avacta Group Plc

Avacta Group Plc

Scale Space

W12 7RZ, London

+44 203 9110353

http://www.avacta.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AVACTA GROUP PLC	-1.39%	+5.19%	+82.05%	-45.80%	41Cr
ARGENX SE	-0.36%	-1.35%	+11.40%	+85.44%	4.3TCr
WUXI APPTEC CO., LTD.	-1.13%	-2.60%	+42.18%	+15.00%	3.92TCr
INSMED INCORPORATED	-0.01%	-0.45%	+82.23%	+661.46%	3.01TCr
BIONTECH SE	+1.21%	-10.16%	-8.32%	-30.06%	2.19TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.71%	-5.01%	+29.53%	-30.75%	1.82TCr
GENMAB A/S	-2.18%	-1.50%	+20.40%	-32.01%	1.6TCr
AKESO, INC.	-0.81%	+2.70%	+53.06%	+171.76%	1.3TCr
SUMMIT THERAPEUTICS INC.	+4.27%	+6.68%	-22.46%	+826.44%	1.25TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.75%	+2.23%	+58.17%	-	1.18TCr
Average	-0.04%	-0.19%	+34.82%	+180.16%	2.06TCr
Weighted average by Cap.	-0.18%	-1.32%	+31.19%	+179.89%